Role and redirection of IgE against cancer

Antibodies

Volumn 2, Issue 2, 2013, Pages 371-391

  Nigro, Elisa A ^a   Siccardi, Antonio G ^a   Vangelista, Luca ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

ADCC; Cancer; CD23; Fc RI; IgE; Immunotherapy

Indexed keywords

CANCER ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CD20 ANTIBODY; CD23 ANTIGEN; CETUXIMAB; CHIMERIC ANTIBODY; ENVELOPE GLYCOPROTEIN 36; ENVELOPE GLYCOPROTEIN 36 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC EPSILON RI RECEPTOR; FC RECEPTOR; FOLATE RECEPTOR 1; GAMMA UROGASTRONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOLOGICAL ADJUVANT; LY 2 ANTIGEN ANTIBODY; LY ANTIGEN; MATUXIMAB; MIMOTOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MOV18; MUCIN 1; MUCIN 1 ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN ANTIBODY; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ALLERGIC REACTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; BASOPHIL; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; MACACA FASCICULARIS; MAST CELL; MOUSE MAMMARY TUMOR ONCOVIRUS; NEOPLASM; NONHUMAN; OVARY CARCINOMA; PLASMA CELL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 84988647798     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib2020371     Document Type: Review

References (106)

1. Johansson, S. G. O. The History of IgE: From discovery to 2010. Curr. Allergy Asthma Rep. 2011, 11, 173-177.
2. Dullaers, M.; De Bruyne, R.; Ramadani, F.; Gould, H. J.; Gevaert, P.; Lambrecht, B. N. The who, where, and when of IgE in allergic airway disease. J. Allergy Clin. Immunol. 2012, 129, 635-645.
3. Gould, H. J.; Sutton, B. J. IgE in allergy and asthma today. Nat. Rev. Immunol. 2008, 8, 205-217.
4. Erazo, A.; Kutchukhidze, N.; Leung, M.; Christ, A. P. G.; Urban, J. F.; Curotto de Lafaille, M. A.; Lafaille, J. J. Unique maturation program of the IgE response in vivo. Immunity 2007, 26, 191-203.
5. Talay, O.; Yan, D.; Brightbill, H. D.; Straney, E. E. M.; Zhou, M.; Ladi, E.; Lee, W. P.; Egen, J. G.; Austin, C. D.; Xu, M.; et al. IgE+ memory B cells and plasma cells generated through a germinalcenter pathway. Nat. Immunol. 2012, 13, 396-404.
6. Yang, Z.; Sullivan, B. M.; Allen, C. D. C. Fluorescent in vivo detection reveals that IgE(+) B cells are restrained by an intrinsic cell fate predisposition. Immunity 2012, 36, 857-872.
7. Jensen-Jarolim, E.; Achatz, G.; Turner, M. C.; Karagiannis, S.; Legrand, F.; Capron, M.; Penichet, M. L.; Rodríguez, J. A.; Siccardi, A. G.; Vangelista, L.; et al. AllergoOncology: The role of IgE-mediated allergy in cancer. Allergy 2008, 63, 1255-1266.
8. Penichet, M. L., Jensen-Jarolim, E., Eds. Cancer and IgE: Introducing the Concept of AllergoOncology, 1st ed.; Springer: New York, NY, USA, 2010; p. 280.
9. Gould, H. J.; Sutton, B. J.; Beavil, A. J.; Beavil, R. L.; McCloskey, N.; Coker, H. A.; Fear, D.; Smurthwaite, L. The biology of IgE and the basis of allergic disease. Annu. Rev. Immunol. 2003, 21, 579-628.
10. Lanzavecchia, A.; Parodi, B. In vitro stimulation of IgE production at a single precursor level by human alloreactive T helper clones. Clin. Exp. Immunol. 1984, 55, 197-203.
11. Cheng, L. E.; Wang, Z.-E.; Locksley, R. M. Murine B cells regulate serum IgE levels in a CD23-dependent manner. J. Immunol. 2010, 185, 5040-5047.
12. Kraft, S.; Kinet, J.-P. New developments in FcepsilonRI regulation, function and inhibition. Nat. Rev. Immunol. 2007, 7, 365-378.
13. Kinet, J. P. The high-affinity IgE receptor (Fc epsilon RI): From physiology to pathology. Annu. Rev. Immunol. 1999, 17, 931-972.
14. Vangelista, L.; Cesco-Gaspere, M.; Lamba, D.; Burrone, O. Efficient folding of the FcepsilonRI alpha-chain membrane-proximal domain D2 depends on the presence of the N-terminal domain D1. J. Mol. Biol. 2002, 322
15. Batista, F. D. F.; Anand, S. S.; Presani, G. G.; Efremov, D. G. D.; Burrone, O. R. O. The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors. J. Exp. Med. 1996, 184, 2197-2205.
16. Vangelista, L.; Soprana, E.; Cesco-Gaspere, M.; Mandiola, P.; Di Lullo, G.; Fucci, R. N.; Codazzi, F.; Palini, A.; Paganelli, G.; Burrone, O. R.; et al. Membrane IgE binds and activates Fc epsilon RI in an antigen-independent manner. J. Immunol. 2005, 174, 5602-5611.
17. Vouldoukis, I.; Mazier, D.; Moynet, D.; Thiolat, D.; Malvy, D.; Mossalayi, M. D. IgE mediates killing of intracellular Toxoplasma gondii by human macrophages through CD23-dependent, interleukin-10 sensitive pathway. PLoS One 2011, 6, e18289.
18. Vouldoukis, I.; Riveros-Moreno, V.; Dugas, B.; Ouaaz, F.; Bécherel, P.; Debré, P.; Moncada, S.; Mossalayi, M. D. The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen. Proc. Natl. Acad. Sci. USA 1995, 92, 7804-7808.
19. Walter, K.; Fulford, A. J. C.; McBeath, R.; Joseph, S.; Jones, F. M.; Kariuki, H. C.; Mwatha, J. K.; Kimani, G.; Kabatereine, N. B.; Vennervald, B. J.; et al. Increased human IgE induced by killing Schistosoma mansoni in vivo is associated with pretreatment Th2 cytokine responsiveness to worm antigens. J. Immunol. 2006, 177, 5490-5498.
20. Cooper, P. J.; Ayre, G.; Martin, C.; Rizzo, J. A.; Ponte, E. V.; Cruz, A. A. Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy 2008, 63, 409-417.
21. Reddy, A.; Fried, B. Atopic disorders and parasitic infections. Adv. Parasitol. 2008, 66, 149-191.
22. Watanabe, N.; Bruschi, F.; Korenaga, M. IgE: A question of protective immunity in Trichinella spiralis infection. Trends Parasitol. 2005, 21, 175-178.
23. Galli, S. J.; Tsai, M. IgE and mast cells in allergic disease. Nat. Med. 2012, 18, 693-704.
24. Gergen, P. J.; Turkeltaub, P. C.; Sempos, C. T. Is allergen skin test reactivity a predictor of mortality? Findings from a national cohort. Clin. Exp. Allergy 2000, 30, 1717-1723.
25. Turner, M. C.; Chen, Y.; Krewski, D.; Ghadirian, P. An overview of the association between allergy and cancer. Int. J. Cancer 2006, 118, 3124-3132.
26. Kero, J.; Gissler, M.; Hemminki, E.; Isolauri, E. Could TH1 and TH2 diseases coexist? Evaluation of asthma incidence in children with coeliac disease, type 1 diabetes, or rheumatoid arthritis: a register study. J. Allergy Clin. Immunol. 2001, 108, 781-783.
27. Olson, S. H.; Chou, J. F.; Ludwig, E.; O'Reilly, E.; Allen, P. J.; Jarnagin, W. R.; Bayuga, S.; Simon, J.; Gonen, M.; Reisacher, W. R.; et al. Allergies, obesity, other risk factors and survival from pancreatic cancer. Int. J. Cancer 2010, 127, 2412-2419.
28. Santillan, A. A.; Camargo, C. A.; Colditz, G. A. A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control 2003, 14, 327-334.
29. Arana, A.; Wentworth, C. E.; Fernández-Vidaurre, C.; Schlienger, R. G.; Conde, E.; Arellano, F. M. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U. K. Br. J. Dermatol. 2010, 163, 1036-1043.
30. Turner, M. C. Epidemiology: Allergy history, IgE, and cancer. Cancer Immunol. Immunother. 2012, 61, 1493-1510.
31. Rittmeyer, D.; Lorentz, A. Relationship between allergy and cancer: an overview. Int. Arch. Allergy Immunol. 2012, 159, 216-225.
32. Van Hemelrijck, M.; Garmo, H.; Binda, E.; Hayday, A.; Karagiannis, S. N.; Hammar, N.; Walldius, G.; Lambe, M.; Jungner, I.; Holmberg, L. Immunoglobulin E and cancer: A metaanalysis and a large Swedish cohort study. Cancer Causes Control 2010, 21, 1657-1667.
33. Brigati, C.; Noonan, D. M.; Albini, A.; Benelli, R. Tumors and inflammatory infiltrates: Friends or foes? Clin. Exp. Metastasis 2002, 19, 247-258.
34. Crivellato, E.; Nico, B.; Ribatti, D. Mast cells and tumour angiogenesis: New insight from experimental carcinogenesis. Cancer Lett. 2008, 269, 1-6.
35. Dabiri, S.; Huntsman, D.; Makretsov, N.; Cheang, M.; Gilks, B.; Badjik, C.; Gelmon, K.; Chia, S.; Hayes, M. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod. Pathol. 2004, 17, 690-695.
36. Sinnamon, M. J.; Carter, K. J.; Sims, L. P.; Lafleur, B.; Fingleton, B.; Matrisian, L. M. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis 2008, 29, 880-886.
37. Ribatti, D.; Molica, S.; Vacca, A.; Nico, B.; Crivellato, E.; Roccaro, A. M.; Dammacco, F. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 2003, 17, 1428-1430.
38. Molin, D.; Edström, A.; Glimelius, I.; Glimelius, B.; Nilsson, G.; Sundström, C.; Enblad, G. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br. J. Haematol. 2002, 119, 122-124.
39. Johansson, A.; Rudolfsson, S.; Hammarsten, P.; Halin, S.; Pietras, K.; Jones, J.; Stattin, P.; Egevad, L.; Granfors, T.; Wikström, P.; et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am. J. Pathol. 2010, 177, 1031-1041.
40. Welsh, T. J.; Green, R. H.; Richardson, D.; Waller, D. A.; O'Byrne, K. J.; Bradding, P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 8959-8967.
41. Dalton, D. K.; Noelle, R. J. The roles of mast cells in anticancer immunity. Cancer Immunol. Immunother. 2012, 61, 1511-1520.
42. Di Carlo, E.; Modesti, A.; Coletti, A.; Colombo, M. P.; Giovarelli, M.; Forni, G.; Diodoro, M. G.; Musiani, P. Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4-or an IL5-transduced tumour. J. Pathol. 1998, 186, 390-397.
43. Valent, P.; Agis, H.; Sperr, W.; Sillaber, C.; Horny, H.-P. Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. Leuk. Lymphoma 2008, 49, 635-638.
44. Munitz, A.; Levi-Schaffer, F. Eosinophils: 'new' roles for 'old' cells. Allergy 2004, 59, 268-275.
45. Fernández-Aceñero, M. J.; Galindo-Gallego, M.; Sanz, J.; Aljama, A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000, 88, 1544-1548.
46. Dorta, R. G.; Landman, G.; Kowalski, L. P.; Lauris, J. R. P.; Latorre, M. R. D. O.; Oliveira, D. T. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 2002, 41, 152-157.
47. Ishibashi, S.; Ohashi, Y.; Suzuki, T.; Miyazaki, S.; Moriya, T.; Satomi, S.; Sasano, H. Tumorassociated tissue eosinophilia in human esophageal squamous cell carcinoma. Anticancer Res. 2006, 26, 1419-1424.
48. von Wasielewski, R.; Seth, S.; Franklin, J.; Fischer, R.; Hübner, K.; Hansmann, M. L.; Diehl, V.; Georgii, A. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000, 95, 1207-1213.
49. Gleich, G. J.; Adolphson, C. R. The eosinophilic leukocyte: Structure and function. Adv. Immunol. 1986, 39, 177-253.
50. Newton, D. L.; Rybak, S. M. Unique recombinant human ribonuclease and inhibition of Kaposi's sarcoma cell growth. J. Natl. Cancer Inst. 1998, 90, 1787-1791.
51. Huland, E.; Huland, H. Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J. Cancer Res. Clin. Oncol. 1992, 118, 463-467.
52. Cormier, S. A.; Taranova, A. G.; Bedient, C.; Nguyen, T.; Protheroe, C.; Pero, R.; Dimina, D.; Ochkur, S. I.; O'Neill, K.; Colbert, D.; et al. Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J. Leukoc. Biol. 2006, 79, 1131-1139.
53. Simson, L.; Ellyard, J. I.; Dent, L. A.; Matthaei, K. I.; Rothenberg, M. E.; Foster, P. S.; Smyth, M. J.; Parish, C. R. Regulation of carcinogenesis by IL-5 and CCL11: A potential role for eosinophils in tumor immune surveillance. J. Immunol. 2007, 178, 4222-4229.
54. Legrand, F.; Driss, V.; Delbeke, M.; Loiseau, S.; Hermann, E.; Dombrowicz, D.; Capron, M. Human eosinophils exert TNF-α and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J. Immunol. 2010, 185, 7443-7451.
55. Leek, R. D.; Lewis, C. E.; Whitehouse, R.; Greenall, M.; Clarke, J.; Harris, A. L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56, 4625-4629.
56. Lin, E. Y.; Li, J.-F.; Bricard, G.; Wang, W.; Deng, Y.; Sellers, R.; Porcelli, S. A.; Pollard, J. W. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol. Oncol. 2007, 1, 288-302.
57. Qian, B.-Z.; Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141, 39-51.
58. Biswas, S. K.; Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat. Immunol. 2010, 11, 889-896.
59. Beatty, G. L.; Chiorean, E. G.; Fishman, M. P.; Saboury, B.; Teitelbaum, U. R.; Sun, W.; Huhn, R. D.; Song, W.; Li, D.; Sharp, L. L.; et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331, 1612-1616.
60. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: Tumorassociated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549-555.
61. Bieber, T. Fc epsilon RI on human epidermal Langerhans cells: An old receptor with new structure and functions. Int. Arch. Allergy Immunol. 1997, 113, 30-34.
62. Lowin, B.; Hahne, M.; Mattmann, C.; Tschopp, J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994, 370, 650-652.
63. Regnault, A.; Lankar, D.; Lacabanne, V.; Rodriguez, A.; Théry, C.; Rescigno, M.; Saito, T.; Verbeek, S.; Bonnerot, C.; Ricciardi-Castagnoli, P.; et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 1999, 189, 371-380.
64. Platzer, B.; Dehlink, E.; Turley, S. J.; Fiebiger, E. How to connect an IgE-driven response with CTL activity? Cancer Immunol. Immunother. 2012, 61, 1521-1525.
65. Parish, C. R. Cancer immunotherapy: The past, the present and the future. Immunol. Cell Biol. 2003, 81, 106-113.
66. Sant, A. J.; Chaves, F. A.; Jenks, S. A.; Richards, K. A.; Menges, P.; Weaver, J. M.; Lazarski, C. A. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II: peptide complexes. Immunol. Rev. 2005, 207, 261-278.
67. Reali, E.; Greiner, J. W.; Corti, A.; Gould, H. J.; Bottazzoli, F.; Paganelli, G.; Schlom, J.; Siccardi, A. G. IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines. Cancer Res. 2001, 61, 5517-5522.
68. Nigro, E. A.; Brini, A. T.; Soprana, E.; Ambrosi, A.; Dombrowicz, D.; Siccardi, A. G.; Vangelista, L. Antitumor IgE adjuvanticity: Key role of Fc epsilon RI. J. Immunol. 2009, 183, 4530-4536.
69. Nigro, E. A.; Soprana, E.; Brini, A. T.; Ambrosi, A.; Yenagi, V. A.; Dombrowicz, D.; Siccardi, A. G.; Vangelista, L. An antitumor cellular vaccine based on a mini-membrane IgE. J. Immunol. 2012, 188, 103-110.
70. Nagy, E.; Berczi, I.; Sehon, A. H. Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol. Immunother. 1991, 34, 63-69.
71. Kershaw, M. H.; Darcy, P. K.; Trapani, J. A.; MacGregor, D.; Smyth, M. J. Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol. Res. 1998, 10, 133-142.
72. Gould, H. J.; Mackay, G. A.; Karagiannis, S. N.; O'Toole, C. M.; Marsh, P. J.; Daniel, B. E.; Coney, L. R.; Zurawski, V. R.; Joseph, M.; Capron, M.; et al. Comparison of IgE and IgG antibodydependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur. J. Immunol. 1999, 29, 3527-3537.
73. Karagiannis, S. N.; Wang, Q.; East, N.; Burke, F.; Riffard, S.; Bracher, M. G.; Thompson, R. G.; Durham, S. R.; Schwartz, L. B.; Balkwill, F. R.; et al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur. J. Immunol. 2003, 33, 1030-1040.
74. Karagiannis, S. N.; Bracher, M. G.; Hunt, J.; McCloskey, N.; Beavil, R. L.; Beavil, A. J.; Fear, D. J.; Thompson, R. G.; East, N.; Burke, F.; et al. IgE-antibody-dependent immunotherapy of solid tumors: Cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J. Immunol. 2007, 179, 2832-2843.
75. Karagiannis, S. N.; Bracher, M. G.; Beavil, R. L.; Beavil, A. J.; Hunt, J.; McCloskey, N.; Thompson, R. G.; East, N.; Burke, F.; Sutton, B. J.; et al. Role of IgE receptors in IgE antibodydependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol. Immunother. 2008, 57, 247-263.
76. Karagiannis, P.; Singer, J.; Hunt, J.; Gan, S. K. E.; Rudman, S. M.; Mechtcheriakova, D.; Knittelfelder, R.; Daniels, T. R.; Hobson, P. S.; Beavil, A. J.; et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol. Immunother. 2009, 58, 915-930.
77. Daniels, T. R.; Leuchter, R. K.; Quintero, R.; Helguera, G.; Rodríguez, J. A.; Martínez-Maza, O.; Schultes, B. C.; Nicodemus, C. F.; Penichet, M. L. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol. Immunother. 2012, 61, 991-1003.
78. Teo, P. Z.; Utz, P. J.; Mollick, J. A. Using the allergic immune system to target cancer: Activity of IgE antibodies specific for human CD20 and MUC1. Cancer Immunol. Immunother. 2012, 61, 2295-2309.
79. Spillner, E.; Plum, M.; Blank, S.; Miehe, M.; Singer, J.; Braren, I. Recombinant IgE antibody engineering to target EGFR. Cancer Immunol. Immunother. 2012, 61, 1565-1573.
80. Daniels-Wells, T. R.; Helguera, G.; Leuchter, R. K.; Quintero, R.; Kozman, M.; Rodríguez, J. A.; Ortiz-Sánchez, E.; Martínez-Maza, O.; Schultes, B. C.; Nicodemus, C. F.; et al. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer 2013, 13, 195.
81. Kershaw, M. H.; Darcy, P. K.; Trapani, J. A.; Smyth, M. J. The use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors. J. Leukoc. Biol. 1996, 60, 721-728.
82. Teng, M. W. L.; Kershaw, M. H.; Jackson, J. T.; Smyth, M. J.; Darcy, P. K. Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy. Hum. Gene Ther. 2006, 17, 1134-1143.
83. Riemer, A. B.; Untersmayr, E.; Knittelfelder, R.; Duschl, A.; Pehamberger, H.; Zielinski, C. C.; Scheiner, O.; Jensen-Jarolim, E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res. 2007, 67, 3406-3411.
84. Sutter, G.; Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 1992, 89, 10847-10851.
85. Benigni, F.; Zimmermann, V. S.; Hugues, S.; Caserta, S.; Basso, V.; Rivino, L.; Ingulli, E.; Malherbe, L.; Glaichenhaus, N.; Mondino, A. Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk. J. Immunol. 2005, 175, 739-748.
86. Dombrowicz, D.; Flamand, V.; Brigman, K. K.; Koller, B. H.; Kinet, J. P. Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene. Cell 1993, 75, 969-976.
87. Yu, P.; Kosco-Vilbois, M.; Richards, M.; Köhler, G.; Lamers, M. C. Negative feedback regulation of IgE synthesis by murine CD23. Nature 1994, 369, 753-756.
88. Dombrowicz, D.; Brini, A. T.; Flamand, V.; Hicks, E.; Snouwaert, J. N.; Kinet, J. P.; Koller, B. H. Anaphylaxis mediated through a humanized high affinity IgE receptor. J. Immunol. 1996, 157, 1645-1651.
89. Di Lullo, G.; Soprana, E.; Panigada, M.; Palini, A.; Erfle, V.; Staib, C.; Sutter, G.; Siccardi, A. G. Marker gene swapping facilitates recombinant modified vaccinia virus Ankara production by host-range selection. J. Virol. Methods 2009, 156, 37-43.
90. Di Lullo, G.; Soprana, E.; Panigada, M.; Palini, A.; Agresti, A.; Comunian, C.; Milani, A.; Capua, I.; Erfle, V.; Siccardi, A. G. The combination of marker gene swapping and fluorescenceactivated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use. J. Virol. Methods 2010, 163, 195-204.
91. Riemer, A. B.; Klinger, M.; Wagner, S.; Bernhaus, A.; Mazzucchelli, L.; Pehamberger, H.; Scheiner, O.; Zielinski, C. C.; Jensen-Jarolim, E. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J. Immunol. 2004, 173, 394-401.
92. Untersmayr, E.; Schöll, I.; Swoboda, I.; Beil, W. J.; Förster-Waldl, E.; Walter, F.; Riemer, A.; Kraml, G.; Kinaciyan, T.; Spitzauer, S.; et al. Antacid medication inhibits digestion of dietary proteins and causes food allergy: A fish allergy model in BALB/c mice. J. Allergy Clin. Immunol. 2003, 112, 616-623.
93. Isaacs, J. D.; Clark, M. R.; Greenwood, J.; Waldmann, H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J. Immunol. 1992, 148, 3062-3071.
94. Mount, P. F.; Sutton, V. R.; Li, W.; Burgess, J.; McKenzie, I. F.; Pietersz, G. A.; Trapani, J. A. Chimeric (mouse/human) anti-colon cancer antibody c30. 6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice. Cancer Res. 1994, 54, 6160-6166.
95. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
96. Hudis, C. A. Trastuzumab-Mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357, 39-51.
97. Ford, A. C.; Grandis, J. R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003, 25, 67-73.
98. Mendelsohn, J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 1997, 3, 2703-2707.
99. Schiller, J. H. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: Focus on matuzumab (EMD 72000). Cancer Invest. 2008, 26, 81-95.
100. Berlyn, K. A.; Schultes, B.; Leveugle, B.; Noujaim, A. A.; Alexander, R. B.; Mann, D. L. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin. Immunol. 2001, 101, 276-283.
101. Neuchrist, C.; Kornfehl, J.; Grasl, M.; Lassmann, H.; Kraft, D.; Ehrenberger, K.; Scheiner, O. Distribution of immunoglobulins in squamous cell carcinoma of the head and neck. Int. Arch. Allergy Immunol. 1994, 104, 97-100.
102. Fu, S. L.; Pierre, J.; Smith-Norowitz, T. A.; Hagler, M.; Bowne, W.; Pincus, M. R.; Mueller, C. M.; Zenilman, M. E.; Bluth, M. H. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin. Exp. Immunol. 2008, 153, 401-409.
103. Untersmayr, E.; Bises, G.; Starkl, P.; Bevins, C. L.; Scheiner, O.; Boltz-Nitulescu, G.; Wrba, F.; Jensen-Jarolim, E. The high affinity IgE receptor Fc epsilonRI is expressed by human intestinal epithelial cells. PLoS One 2010, 5, e9023.
104. Rudman, S. M.; Josephs, D. H.; Cambrook, H.; Karagiannis, P.; Gilbert, A. E.; Dodev, T.; Hunt, J.; Koers, A.; Montes, A.; Taams, L.; et al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcRI-mediated basophil activation by a tumourspecific IgE antibody to evaluate the risk of type I hypersensitivity. Clin. Exp. Allergy 2011, 41, 1400-1413.
105. Jensen-Jarolim, E.; Singer, J. Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology? Clin. Exp. Allergy 2011, 41, 1337-1340.
106. Karagiannis, S. N.; Josephs, D. H.; Karagiannis, P.; Gilbert, A. E.; Saul, L.; Rudman, S. M.; Dodev, T.; Koers, A.; Blower, P. J.; Corrigan, C.; et al. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol. Immunother. 2012, 61, 1547-1564.